Dyne Therapeutics, Inc. Operating Income
Dyne Therapeutics, Inc. (DYN) reported Operating Income of -$181.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-07-29
- Dyne Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$181.66M.
- Dyne Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$125.28M.
- Dyne Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$116.13M.
- Dyne Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$113.89M.
- Dyne Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$468.18M.
- Dyne Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$343.89M.
- Dyne Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$242.16M.
- Dyne Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$170.96M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$181.66M 10-Q · filed 2026-07-29 | -$306.94M 10-Q · filed 2026-07-29 | -$423.07M derived: sum of 3 quarters · filed 2026-07-29 | -$536.96M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | -$125.28M 10-Q · filed 2026-05-11 | -$241.41M derived: sum of 2 quarters · filed 2026-05-11 | -$355.30M derived: sum of 3 quarters · filed 2026-05-11 | -$471.09M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | -$116.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$230.02M derived: sum of 2 quarters · filed 2026-03-02 | -$345.81M derived: sum of 3 quarters · filed 2026-07-29 | -$468.18M 10-K · filed 2026-03-02 | |
| 2025-09-30 | -$113.89M 10-Q · filed 2025-11-05 | -$229.68M derived: sum of 2 quarters · filed 2026-07-29 | -$352.06M 10-Q · filed 2025-11-05 | -$449.16M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | -$115.79M 10-Q · filed 2026-07-29 | -$238.16M 10-Q · filed 2026-07-29 | -$335.27M derived: sum of 3 quarters · filed 2026-07-29 | -$440.84M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | -$122.37M 10-Q · filed 2026-05-11 | -$219.48M derived: sum of 2 quarters · filed 2026-05-11 | -$325.05M derived: sum of 3 quarters · filed 2026-05-11 | -$397.01M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$97.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$202.68M derived: sum of 2 quarters · filed 2026-03-02 | -$274.64M derived: sum of 3 quarters · filed 2026-03-02 | -$343.89M 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$105.57M 10-Q · filed 2025-11-05 | -$105.66M 10-Q · filed 2024-11-12 | -$177.53M derived: sum of 2 quarters · filed 2025-11-05 | -$246.78M 10-Q · filed 2025-11-05 | -$314.38M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$71.96M 10-Q · filed 2025-07-28 | -$141.12M 10-Q · filed 2025-07-28 | -$208.81M derived: sum of 3 quarters · filed 2026-03-02 | -$271.08M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-03-31 | -$69.16M 10-Q · filed 2025-05-08 | -$136.84M derived: sum of 2 quarters · filed 2026-03-02 | -$199.12M derived: sum of 3 quarters · filed 2026-03-02 | -$265.85M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2023-12-31 | -$67.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$129.96M derived: sum of 2 quarters · filed 2026-03-02 | -$196.70M derived: sum of 3 quarters · filed 2026-03-02 | -$242.16M 10-K · filed 2026-03-02 | |
| 2023-09-30 | -$62.27M 10-Q · filed 2024-11-12 | -$129.01M derived: sum of 2 quarters · filed 2024-11-12 | -$174.47M 10-Q · filed 2024-11-12 | -$214.62M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$66.74M 10-Q · filed 2024-08-12 | -$112.20M 10-Q · filed 2024-08-12 | -$152.34M derived: sum of 3 quarters · filed 2025-02-27 | -$194.62M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$45.46M 10-Q · filed 2024-05-02 | -$85.61M derived: sum of 2 quarters · filed 2025-02-27 | -$127.89M derived: sum of 3 quarters · filed 2025-02-27 | -$180.64M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | -$40.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$82.42M derived: sum of 2 quarters · filed 2025-02-27 | -$135.18M derived: sum of 3 quarters · filed 2025-02-27 | -$170.96M 10-K · filed 2025-02-27 | |
| 2022-09-30 | -$42.28M 10-Q · filed 2023-10-30 | -$95.03M derived: sum of 2 quarters · filed 2023-10-30 | -$130.82M 10-Q · filed 2023-10-30 | -$182.78M derived: sum of 4 quarters · filed 2023-10-30 | |
| 2022-06-30 | -$52.76M 10-Q · filed 2023-08-03 | -$88.54M 10-Q · filed 2023-08-03 | -$140.50M derived: sum of 3 quarters · filed 2023-08-03 | -$183.26M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | -$35.78M 10-Q · filed 2023-05-11 | -$87.74M derived: sum of 2 quarters · filed 2023-05-11 | -$130.51M derived: sum of 3 quarters · filed 2023-05-11 | -$160.67M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$51.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$94.73M derived: sum of 2 quarters · filed 2023-03-02 | -$124.89M derived: sum of 3 quarters · filed 2023-03-02 | -$150.03M 10-K · filed 2023-03-02 | |
| 2021-09-30 | -$42.77M 10-Q · filed 2022-11-03 | -$72.93M derived: sum of 2 quarters · filed 2022-11-03 | -$98.06M 10-Q · filed 2022-11-03 | -$126.67M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$30.16M 10-Q · filed 2022-08-04 | -$55.30M 10-Q · filed 2022-08-04 | -$83.90M derived: sum of 3 quarters · filed 2022-08-04 | -$97.42M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$25.13M 10-Q · filed 2022-05-02 | -$53.73M derived: sum of 2 quarters · filed 2022-05-02 | -$67.25M derived: sum of 3 quarters · filed 2022-05-02 | -$75.93M derived: sum of 4 quarters · filed 2022-05-02 | |
| 2020-12-31 | -$28.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$42.12M derived: sum of 2 quarters · filed 2022-03-10 | -$50.80M derived: sum of 3 quarters · filed 2022-03-10 | -$58.65M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$13.52M 10-Q · filed 2021-11-04 | -$22.20M derived: sum of 2 quarters · filed 2021-11-04 | -$30.05M 10-Q · filed 2021-11-04 | -$35.52M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$8.68M 10-Q · filed 2021-08-05 | -$16.53M 10-Q · filed 2021-08-05 | -$22.00M derived: sum of 3 quarters · filed 2021-08-05 | -$25.63M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$7.85M 10-Q · filed 2021-05-06 | -$13.32M derived: sum of 2 quarters · filed 2021-05-06 | -$16.95M derived: sum of 3 quarters · filed 2021-05-06 | ||
| 2019-12-31 | -$5.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$9.10M derived: sum of 2 quarters · filed 2021-03-04 | -$13.83M 10-K · filed 2021-03-04 | ||
| 2019-09-30 | -$3.63M 10-Q · filed 2020-11-05 | -$8.36M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |